Hong Kong Stock Movement | BEIGENE (06160) Opens Over 3% Higher, Announces Commercial Launch of Baiyueda® in China, First Batch to Cover 70 Cities Nationwide

Stock News01-14

BEIGENE (06160) opened over 3% higher, with a gain of 3.33% to HK$210.8 at the time of writing, and a turnover of HK$16.7872 million.

On January 14, the company announced via its official WeChat account that its self-developed Class 1 innovative drug, the novel BCL2 inhibitor Baiyueda® (Sotoclax), began supply on January 13, with the initial batch of medication set to reach 70 cities across the country.

On the same day, prescriptions were issued by numerous medical institutions nationwide, enabling Sotoclax to begin benefiting adult patients in China with treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

Previously, based on positive results from the BGB-11417-201 and BGB-11417-202 clinical studies, Sotoclax received conditional approval from the National Medical Products Administration (NMPA) on December 30, 2025.

Study results confirmed that in patients with treated CLL/SLL and R/R MCL, Sotoclax demonstrated clinically meaningful remission benefits, alongside an overall favorable tolerability and safety profile.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124618498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124618498","market":"nz","top_or_hot":-1,"title":"Hong Kong Stock Movement | BEIGENE (06160) Opens Over 3% Higher, Announces Commercial Launch of Baiyueda® in China, First Batch to Cover 70 Cities Nationwide","media":"Stock News","content":"<p>BEIGENE (06160) opened over 3% higher, with a gain of 3.33% to HK$210.8 at the time of writing, and a turnover of HK$16.7872 million.</p>\n<p>On January 14, the company announced via its official WeChat account that its self-developed Class 1 innovative drug, the novel BCL2 inhibitor Baiyueda® (Sotoclax), began supply on January 13, with the initial batch of medication set to reach 70 cities across the country.</p>\n<p>On the same day, prescriptions were issued by numerous medical institutions nationwide, enabling Sotoclax to begin benefiting adult patients in China with treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).</p>\n<p>Previously, based on positive results from the BGB-11417-201 and BGB-11417-202 clinical studies, Sotoclax received conditional approval from the National Medical Products Administration (NMPA) on December 30, 2025.</p>\n<p>Study results confirmed that in patients with treated CLL/SLL and R/R MCL, Sotoclax demonstrated clinically meaningful remission benefits, alongside an overall favorable tolerability and safety profile.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | BEIGENE (06160) Opens Over 3% Higher, Announces Commercial Launch of Baiyueda® in China, First Batch to Cover 70 Cities Nationwide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | BEIGENE (06160) Opens Over 3% Higher, Announces Commercial Launch of Baiyueda® in China, First Batch to Cover 70 Cities Nationwide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-14 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIGENE (06160) opened over 3% higher, with a gain of 3.33% to HK$210.8 at the time of writing, and a turnover of HK$16.7872 million.</p>\n<p>On January 14, the company announced via its official WeChat account that its self-developed Class 1 innovative drug, the novel BCL2 inhibitor Baiyueda® (Sotoclax), began supply on January 13, with the initial batch of medication set to reach 70 cities across the country.</p>\n<p>On the same day, prescriptions were issued by numerous medical institutions nationwide, enabling Sotoclax to begin benefiting adult patients in China with treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).</p>\n<p>Previously, based on positive results from the BGB-11417-201 and BGB-11417-202 clinical studies, Sotoclax received conditional approval from the National Medical Products Administration (NMPA) on December 30, 2025.</p>\n<p>Study results confirmed that in patients with treated CLL/SLL and R/R MCL, Sotoclax demonstrated clinically meaningful remission benefits, alongside an overall favorable tolerability and safety profile.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1124618498","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124618498","pubTimestamp":1768354465,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BEIGENE (06160) opened over 3% higher, with a gain of 3.33% to HK$210.8 at the time of writing, and a turnover of HK$16.7872 million. On January 14, the company announced via its official WeChat...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","BK1161":"生物科技","BK1500":"做空集合股","BK1588":"回港中概股","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK4585":"ETF&股票定投概念","BK1583":"高瓴概念","BK4526":"热门中概股","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4139":"生物科技","ONC":"百济神州","BK0239":"医药制造","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","06160":"百济神州"},"translate_title":"港股动向|百济神州(06160)高开超3%宣布商业推出百悦达®在中国，首批覆盖全国70个城市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"06160":1,"ONC":1},"content_text":"BEIGENE (06160) opened over 3% higher, with a gain of 3.33% to HK$210.8 at the time of writing, and a turnover of HK$16.7872 million.\nOn January 14, the company announced via its official WeChat account that its self-developed Class 1 innovative drug, the novel BCL2 inhibitor Baiyueda® (Sotoclax), began supply on January 13, with the initial batch of medication set to reach 70 cities across the country.\nOn the same day, prescriptions were issued by numerous medical institutions nationwide, enabling Sotoclax to begin benefiting adult patients in China with treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).\nPreviously, based on positive results from the BGB-11417-201 and BGB-11417-202 clinical studies, Sotoclax received conditional approval from the National Medical Products Administration (NMPA) on December 30, 2025.\nStudy results confirmed that in patients with treated CLL/SLL and R/R MCL, Sotoclax demonstrated clinically meaningful remission benefits, alongside an overall favorable tolerability and safety profile.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124618498","isCrawlerRequest":true}